Budesonide inhalation suspension - Sheffield
Latest Information Update: 19 Dec 2021
At a glance
- Originator Sheffield Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 17 Jun 2003 Sheffield Pharmaceuticals has filed for protection under Chapter 7 bankruptcy laws
- 17 Jun 2003 Discontinued - Phase-I for Asthma in USA (Inhalation)
- 15 Mar 2002 Sheffield has completed a phase I clinical study with nebulised nanobudesonide in healthy volunteers